276 related articles for article (PubMed ID: 25595836)
21. Dissecting MMP P
Tokmina-Roszyk M; Fields GB
J Biol Chem; 2018 Oct; 293(43):16661-16676. PubMed ID: 30185620
[TBL] [Abstract][Full Text] [Related]
22. CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase.
Suenaga N; Mori H; Itoh Y; Seiki M
Oncogene; 2005 Jan; 24(5):859-68. PubMed ID: 15558018
[TBL] [Abstract][Full Text] [Related]
23. The interface between catalytic and hemopexin domains in matrix metalloproteinase-1 conceals a collagen binding exosite.
Arnold LH; Butt LE; Prior SH; Read CM; Fields GB; Pickford AR
J Biol Chem; 2011 Dec; 286(52):45073-82. PubMed ID: 22030392
[TBL] [Abstract][Full Text] [Related]
24. Exosite interactions impact matrix metalloproteinase collagen specificities.
Robichaud TK; Steffensen B; Fields GB
J Biol Chem; 2011 Oct; 286(43):37535-42. PubMed ID: 21896477
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions.
Xu X; Chen Z; Wang Y; Bonewald L; Steffensen B
Biochem J; 2007 Aug; 406(1):147-55. PubMed ID: 17516913
[TBL] [Abstract][Full Text] [Related]
26. Second Generation Triple-Helical Peptide Inhibitors of Matrix Metalloproteinases.
Bhowmick M; Tokmina-Roszyk D; Onwuha-Ekpete L; Harmon K; Robichaud T; Fuerst R; Stawikowska R; Steffensen B; Roush W; Wong HR; Fields GB
J Med Chem; 2017 May; 60(9):3814-3827. PubMed ID: 28394608
[TBL] [Abstract][Full Text] [Related]
27. Biochemical characterization of the catalytic domain of membrane-type 4 matrix metalloproteinase.
Kolkenbrock H; Essers L; Ulbrich N; Will H
Biol Chem; 1999 Sep; 380(9):1103-8. PubMed ID: 10543448
[TBL] [Abstract][Full Text] [Related]
28. The recognition of collagen and triple-helical toolkit peptides by MMP-13: sequence specificity for binding and cleavage.
Howes JM; Bihan D; Slatter DA; Hamaia SW; Packman LC; Knauper V; Visse R; Farndale RW
J Biol Chem; 2014 Aug; 289(35):24091-101. PubMed ID: 25008319
[TBL] [Abstract][Full Text] [Related]
29. A synergy between the catalytic and structural Zn(II) ions and the enzyme and substrate dynamics underlies the structure-function relationships of matrix metalloproteinase collagenolysis.
Varghese A; Chaturvedi SS; Fields GB; Karabencheva-Christova TG
J Biol Inorg Chem; 2021 Aug; 26(5):583-597. PubMed ID: 34228191
[TBL] [Abstract][Full Text] [Related]
30. Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2.
Xu X; Chen Z; Wang Y; Yamada Y; Steffensen B
Biochem J; 2005 Nov; 392(Pt 1):127-34. PubMed ID: 16008524
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinase expression and function during fin regeneration in zebrafish: analysis of MT1-MMP, MMP2 and TIMP2.
Bai S; Thummel R; Godwin AR; Nagase H; Itoh Y; Li L; Evans R; McDermott J; Seiki M; Sarras MP
Matrix Biol; 2005 Jun; 24(4):247-60. PubMed ID: 15935631
[TBL] [Abstract][Full Text] [Related]
32. Triple-helical peptide analysis of collagenolytic protease activity.
Lauer-Fields JL; Fields GB
Biol Chem; 2002; 383(7-8):1095-105. PubMed ID: 12437092
[TBL] [Abstract][Full Text] [Related]
33. Strategies for MMP inhibition in cancer: innovations for the post-trial era.
Overall CM; López-Otín C
Nat Rev Cancer; 2002 Sep; 2(9):657-72. PubMed ID: 12209155
[TBL] [Abstract][Full Text] [Related]
34. Identification of Broad-Spectrum MMP Inhibitors by Virtual Screening.
Gimeno A; Cuffaro D; Nuti E; Ojeda-Montes MJ; Beltrán-Debón R; Mulero M; Rossello A; Pujadas G; Garcia-Vallvé S
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361703
[TBL] [Abstract][Full Text] [Related]
35. Elucidating the function of non catalytic domains of collagenases and aggrecanases.
Nagase H; Fushimi K
Connect Tissue Res; 2008; 49(3):169-74. PubMed ID: 18661336
[TBL] [Abstract][Full Text] [Related]
36. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
[TBL] [Abstract][Full Text] [Related]
37. Matrix metalloproteinase triple-helical peptidase activities are differentially regulated by substrate stability.
Minond D; Lauer-Fields JL; Nagase H; Fields GB
Biochemistry; 2004 Sep; 43(36):11474-81. PubMed ID: 15350133
[TBL] [Abstract][Full Text] [Related]
38. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
39. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
40. Clinical Implications of Compounds Designed to Inhibit ECM-Modifying Metalloproteinases.
Amar S; Minond D; Fields GB
Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 28613012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
